Lifeboat Foundation

Genentech’s Gregory Rippon, M.D., associates a few different phrases with the challenging nature of Alzheimer’s disease drug development: “cautious optimism,” “steady progress,” “an exercise in per | Genentech has been working on gantenerumab for 20 years, and, while it’s tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence.

CMS officials disagree with the FDA’s reasoning, and are likely worried about the cost of covering a medication for hundreds of thousands of beneficiaries who might seek the treatment if it was broadly covered by Medicare. While CMS’s concern for taxpayers is understandable, it’s the FDA — not CMS — that has the statutory authority and deep medical expertise to assess a drug for approval. And Aduhelm passed the FDA’s assessment.

CMS arguably overstepped the bounds of its authority. Its decision is a huge blow to millions of Americans living with Alzheimer’s and their families. They are the losers in CMS’s decision, not only from the severe restriction on access to Aduhelm but also from its chilling effect on the development of other disease-modifying agents for people with Alzheimer’s. If CMS won’t pay for a treatment after the FDA legally approves it, why should a company bother pursuing this pathway?

CMS’s decision will affect the exploration for new treatments for Alzheimer’s for years, just at the time when new drugs appear to be making progress against this terrible disease.

EasyJet said it had to scrap hundreds of flights due to staffers being infected with COVID-19.

An analysis of the genetic material in the ocean has identified thousands of previously unknown RNA viruses and doubled the number of phyla, or biological groups, of viruses thought to exist, according to a new study our team of researchers has published in the journal Science.

RNA viruses are best known for the diseases they cause in people, ranging from the common cold to COVID-19. They also infect plants and animals important to people.

Continue reading “Over 5,000 Previously Unknown Viruses Have Been Discovered Lurking in The Oceans” »

Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.

Summary: Patients who suffer from frontotemporal dementia with extrapyramidal symptoms have brainstem atrophy and reduced metabolic activity in specific brain regions compared to those with FTD without extrapyramidal symptoms.

Source: University of Eastern Finland.

Frontotemporal dementia patients with extrapyramidal symptoms have brainstem atrophy and reduced metabolism in certain areas of the brain significantly more often than patients without extrapyramidal symptoms, a new study from the University of Eastern Finland shows. This observation can facilitate differential diagnostics in frontotemporal dementia.

Not a solution, but a positive and interesting step. 2 mins.

Researchers have rejuvenated a 53-year-old woman’s skin cells so they are the equivalent of a 23-year-old’s.

Continue reading “Science rejuvenates woman’s skin cells to 30 years younger — BBC News” »

A unprecedented global study of Alzheimer’s disease has uncovered an additional 42 genes that may affect a person’s risk of developing the disorder. Doctors hope to use that information to develop a more precise way to identify risk.

The researchers looked at multiple measures of cellular age. First, they used the epigenetic clock, where chemical tags throughout the genome indicate age. Secondly, they looked at the transcriptome, all the gene readouts produced by the cell. By these two measures, the reprogrammed cells matched the profile of cells that were 30 years younger, compared to reference data sets. In other words, cells from a woman of 53 now appeared like those of a woman aged 23.

The potential applications of this technique are dependent on cells not only appearing younger, but functioning like young cells too. Fibroblasts produce collagen – a molecule found in bones, skin tendons, and ligaments, helping provide structure to tissues and heal wounds. In this study, the rejuvenated fibroblasts produced more collagen proteins compared to control cells that did not undergo the reprogramming process. Fibroblasts also move into areas that need repairing. Researchers tested the partially rejuvenated cells by creating an artificial cut in a layer of cells in a dish, seen in the video below. The treated fibroblasts moved into the gap faster than older cells. This is a promising sign that one day this research could eventually be used to create cells that are better at healing wounds.

In the future, this research may also open up other therapeutic possibilities; the researchers observed that their method also influenced other genes linked to age-related diseases and symptoms. The APBA2 gene – associated with Alzheimer’s, and the MAF gene with a role in the development of cataracts – both showed changes towards youthful levels of transcription.